Statins are known to exert a number of biological effects apart from reducing cholesterol synthesis. The results of recent studies indicate that patients treated with pravastatin have a lower prevalence of diagnosed Alzheimer’s disease (AD). These observations prompted us to examine the effects of pravastatin on Alzheimer’s peptide (Aβ1–42)-induced pro-inflammatory activation in the human glioma cell line in vitro. Cells alone or cells pre-treated with pravastatin (0.1 mg ml−1) for 24 h were stimulated with 5 μM of freshly dissolved Aβ1–42 for the next 24 h. The pre-treatment of cells with pravastatin diminished the capacity of Aβ to induce metalloproteinases, cytokine IL-6 and free radical levels. Although both pravastatin and Aβ1–42 separately increased PPARγ activity, the combination of Aβ1–42 and pravastatin resulted in no effect on PPARγ expression. These data indicate that soluble forms of Aβ1–42, which are a potent stimulus of pro-inflammatory activation of glioma cells in vitro, could be a good target for pravastatin.
- Farmakologi och toxikologi